Ataraxis develops artificial intelligence methods to integrate multi-modal data for cancer prognosis and treatment selection, addressing previously unsolvable problems in cancer care.

Ataraxis

Ataraxis AI | 1,052 followers on LinkedIn. Transforming Cancer Care with AI Precision Medicine | Ataraxis is an AI precision medicine company transforming cancer diagnostics and patient outcomes through the power of AI. We are addressing previously unsolvable problems in cancer prognosis and treatment selection through cutting-edge foundation models and multi-modal data. 

Our first clinically validated offering, Ataraxis Breast, is the world’s first AI-native prognostic/predictive test for breast cancer and provides greater accuracy than standard of care genomic assays.

CSR at ataraxis

naomi gomez

CEO & Founder at Ataraxis AI

Jan Witowski MD PhD

Machine Learning Engineer at Stealth AI Startup | MSc Data Science Candidate at NYU

Ken Zeng

Student at NYU Tandon School of Engineering

Michael Bian

Ataraxis AI

Today, we are launching Ataraxis AI to fulfill the promise of precision medicine. At Ataraxis, we are pioneering a new era of AI-native diagnostic tests that answer questions about patient outcomes and treatment response with greater accuracy, faster turnaround times, and broader applicability than molecular tests. Our first product, Ataraxis Breast, is the world's first AI-native prognostic/predictive test for breast cancer. Validated in a study of 8,161 patients across 15 cohorts from seven countries, this landmark study demonstrated that Ataraxis Breast: 📌 Delivers up to 30% higher accuracy than standard-of-care molecular diagnostics 📌 Works across all breast cancer subtypes, expanding testing to 100,000 more patients each year 📌 Is faster, more cost-effective, and capable of addressing new clinical questions Ataraxis Breast is powered by Kestrel, our state-of-the-art AI foundation model for digital pathology. Kestrel is a pan-cancer model that provides new insights into cancer, enabling predictions for patient and treatment outcomes in breast cancer and beyond. Developed using the latest AI methodologies—including self-supervised learning and vision transformers—Kestrel was created with guidance from our special advisor, Yann LeCun . Last year, we raised $4M in a round co-led by Giant Ventures and Obvious Ventures . Thank you to our investors, team, and supporters. Learn more about today's announcement here: https://lnkd.in/embW5s7g . #AI #PrecisionMedicine #CancerDiagnostics #BreastCancer #CancerCare

“The entire mission of our company is to start providing information and answers to questions where there was no alternative.” Today in Forbes, Alex Knapp covers our founding story, our first product, and our mission to create tests that predict patient outcomes and personalize treatments for at least 50% of the 26 million new cancer patients expected to be diagnosed globally by 2030.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 9, 2024 11:32 AM	77d4e089
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 9, 2024 11:32 AM	d637a4bf
crunchbase trigger	general	Nov 27, 2024 12:50 PM	3bff009b
crunchbase profile	general
li profile	general	Nov 9, 2024 11:32 AM	2892e09c
translate crunchbase fundingrounds	general
peers	general	Nov 9, 2024 11:32 AM	090789ac
news basic	general	Nov 9, 2024 11:32 AM	69123252
bundesanzeiger	filings
financials download nd	financials
private financials	financials

ATAR

AI:ATARAXIS

Ataraxis